Malin Corporation plc

ISE:MLC Stock Report

Market Cap: €114.3m

Malin Valuation

Is MLC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MLC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MLC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MLC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MLC?

Key metric: As MLC is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for MLC. This is calculated by dividing MLC's market cap by their current book value.
What is MLC's PB Ratio?
PB Ratio1x
Book€118.20m
Market Cap€114.28m

Price to Book Ratio vs Peers

How does MLC's PB Ratio compare to its peers?

The above table shows the PB ratio for MLC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average5.2x
NANOFH Nanoform Finland Oyj
1.7x28.4%€114.6m
PCA PCAS
15.3xn/a€109.9m
A038290 Macrogen
1.1x112.2%₩160.4b
DXRX Diaceutics
2.6x83.5%UK£99.3m
MLC Malin
1xn/a€114.3m

Price-To-Book vs Peers: MLC is good value based on its Price-To-Book Ratio (1x) compared to the peer average (5.2x).

Price to Book Ratio vs Industry

How does MLC's PB Ratio compare vs other companies in the European Life Sciences Industry?

2 CompaniesPrice / BookEstimated GrowthMarket Cap
MLC 1.0xIndustry Avg. 3.3xNo. of Companies8PB0246810+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: MLC is good value based on its Price-To-Book Ratio (1x) compared to the European Life Sciences industry average (3.2x).

Price to Book Ratio vs Fair Ratio

What is MLC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MLC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate MLC's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MLC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€6.05
€11.71
+93.5%
32.4%€15.50€7.91n/a2
Nov ’25€5.80
€11.71
+101.8%
32.4%€15.50€7.91n/a2
Oct ’25€6.10
€11.71
+91.9%
32.4%€15.50€7.91n/a2
Sep ’25€6.45
€11.71
+81.5%
32.4%€15.50€7.91n/a2
Aug ’25€5.90
€11.71
+98.4%
32.4%€15.50€7.91n/a2
Jul ’25€5.90
€11.71
+98.4%
32.4%€15.50€7.91n/a2
Jun ’25€5.70
€11.71
+105.4%
32.4%€15.50€7.91n/a2
May ’25€5.40
€11.71
+116.8%
32.4%€15.50€7.91n/a2
Apr ’25€5.80
€11.71
+101.8%
32.4%€15.50€7.91n/a2
Mar ’25€5.60
€11.71
+109.0%
32.4%€15.50€7.91n/a2
Feb ’25€5.10
€11.15
+118.6%
39.0%€15.50€6.80n/a2
Jan ’25€4.50
€11.15
+147.8%
39.0%€15.50€6.80n/a2
Dec ’24€4.42
€11.15
+152.3%
39.0%€15.50€6.80n/a2
Nov ’24€4.06
€11.15
+174.6%
39.0%€15.50€6.80€5.802
Oct ’24€4.54
€11.15
+145.6%
39.0%€15.50€6.80€6.102
Sep ’24€4.40
€12.30
+179.5%
26.0%€15.50€9.10€6.452
Aug ’24€4.36
€12.30
+182.1%
26.0%€15.50€9.10€5.902

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies